Objective: Given the presence of a pathological immune response in sporadic vestibular schwannoma (sVS), this study aims to explore the roles of aspirin in minimizing sVS growth in vivo. 
Sporadic vestibular schwannomas (sVS), also known as acoustic neuromas, are benign nerve sheath tumors that mostly arise from the schwann cells of the superior and inferior vestibular part of the VIIIth cranial nerve. sVS are unilateral and account for 95% of all vestibular schwannomas (VS) (1) . VS make up 80% of cerebellopontine angle (CPA) tumors and 8% of all intracranial tumors (2) . VS have a clinical incidence of 1 per 10,000 individuals (3), although the subclinical rates are estimated to be higher, based on the histologic incidence of 1 per 100 (4) .
The tumors arise within the internal auditory canal and typically extend into the CPA, causing dysfunction of the nearby structures such as the inner ear, which contributes to hearing loss (5), or brainstem compression, which is associated with cranial neuropathies and even death (6, 7) . Currently, a patient diagnosed with sVS can elect conservative management through serial MRI scans if the tumor and its associated morbidities are stable. If sVS growth is significant or symptomatic, options for management include surgical resection via craniotomy or stereotactic radiation therapy. A drug therapy against VS would obviate the need for invasive therapy and may augment the efficacy of the existing modalities when the more aggressive approaches are dictated by the tumor size.
To expedite the development of effective and welltolerated pharmacotherapies for sVS, it is important to understand sVS pathobiology and identify clinically used medicines that may be utilized to manipulate the sVS biology. The establishment of significant roles of several molecular targets of anti-inflammatory medications in sVS pathogenesis suggests that anti-inflammatory medications may be a means to retard sVS growth. Cyclooxygenase-2 (COX-2), a prominent target of aspirin, is a key enzyme in prostaglandin biosynthesis (8) . The enzyme is present at high levels in majority of sVS, and its expression was found to be correlated with a high proliferation rate in the tumor (9) . COX-2 is upregulated in various solid tumors, including different types of breast cancer and colon cancer, both known to be modulated by anti-inflammatory medications, including aspirin (10, 11) . Consistent with sVS having a pathologic inflammatory component, a recent histologic study found the density of tumor-associated macrophages to be correlated with the rate of volumetric growth (12) .
We performed a bioinformatics-based network analysis on previously validated, aberrantly functional genes in sVS and identified nuclear factor kappa B (NF-JB), a transcription factor known to orchestrate the immunogenic response, to be a key modulator in sVS tumorigenesis (manuscript in preparation). This finding suggests that alteration of NF-JB signaling may halt tumor progression. Anti-inflammatory medications, such as aspirin, are known to inhibit NF-JB activation (13) . NF-JB, in turn, can promote COX-2 expression, providing another mechanism through which aspirin can mediate inflammation (14) . Because the pathobiology of sVS and VS associated with NF2 are known to overlap (15) , our aim to understand the effect of inflammatory inhibition is further motivated by the current clinical trial assessing the efficacy of rapamycin, an immunosuppressant drug, in stabilizing the growth of tumors associated with NF2 (ClinicalTrials.gov ID NCT01345136).
Taken together, our unpublished findings combined with others' published work lead us to hypothesize that aspirin intake is inversely associated with sVS growth. To test the hypothesis, we carried out a retrospective case study of 689 patients with sVS followed at our institution. We focused on patients whose tumors were monitored with serial MRI scans to investigate a clinical correlation between the rate of tumor progression and aspirin intake.
MATERIALS AND METHODS

Experimental Design
A retrospective case review of patients diagnosed with sVS at Massachusetts Eye and Ear Infirmary from January 1, 1980, to April 1, 2012, was carried out to identify patients whose tumor growth was followed by serial MRI scans for at least 4 months. The study was approved by the institutional review board (HSC protocol Number: 12-036H, P.I.: K.M.S.). Pertinent medical information was extracted from charts and electronic medical records. The patients' intake of aspirin was noted whenever recorded. Patients' comorbidities that would warrant long-term aspirin use were extracted. Patients were grouped into 2 groups: those taking aspirin (''aspirin users'') and those not taking aspirin (''nonusers''). To qualify as aspirin user, a patient needed to have documented history of aspirin intake; all users had at least one comorbidity that warranted long-term aspirin use or met the age criterion for aspirin prophylaxis against myocardial infarct (age 45 or older in men) or stroke (age 55 or older in women) (16) . The tumor size was recorded in 3 dimensions: anteroposterior, superoinferior or transverse. For tumors that were not confined to the internal auditory canal at the time of diagnosis, tumor size was defined as the size of the cerebellopontine angle extension. Tumors were categorized as growing if they increased in any dimension on serial MRI scans or not growing if they were stable or shrinking in any dimension on serial MRI scans. The tumor growth rate was expressed in mm/year (mm/yr). There were 2 study outcomes when comparing aspirin users and nonusers: a categorized change in tumor size (no growth versus growth) and annual sVS size change (in mm/yr). As age is an important variable that influences therapeutic decisions, age adjustment was carried out to make age distributions similar between aspirin users and nonusers. To this end, cases from the nonuser pool were removed that did not have corresponding age-matched aspirin users. Although age matching was not conducted for every case, the average and the range for the aspirin users and nonusers were closely matched.
Statistical Analysis
Five distinct analyses were performed using STATA version 12.1. First, the difference in proportion of sVS demonstrating growth versus no growth was compared between the aspirin users and nonusers using a Fisher's exact test (p G 0.05 was considered significant). This test was appropriate for our samples size. Second, multiple logistic regression was used to determine if age and sex were potential confounders. Third, a Fisher's exact test was performed after age-adjusting aspirin users and nonusers. For analyses 1 and 3, odds ratio (OR) and the corresponding 95% confidence interval (CI) were calculated. Fourth, the average tumor growth rate (in mm/yr) was compared between aspirin users and nonusers using an independent sample t test (null hypothesis H o : mean tumor growth rates are equal; p G 0.05 was considered significant) because the data from the 2 groups were independent and similarly distributed. Fifth, the tumor size at the time of the first MRI scan was compared between the aspirin users and nonusers using an independent sample t test (null hypothesis H o : mean tumor sizes are equal; p G 0.05 was considered significant). The same test was also performed to compare age distribution in the nonusers, age-adjusted nonusers, and aspirin users.
RESULTS
Of the 689 patients with sVS identified during the study period, 122 (18%) were aspirin users, and 567 (82%) were nonusers ( Table 1) . Of the 347 patients (50%) whose a Tumor growth was defined as 90 mm/year change in serial MRI scans conducted at least 4 months apart. b Age adjustment was performed by eliminating patients from the nonusers so that the aspirin users and age-adjusted nonusers are not statistically significant in age.
tumors were followed by serial MRI scans, 81 (23%) were aspirin users and 266 (77%) were nonusers (Table 1) . Among the aspirin users, 38 patients took 81 mg (baby strength) daily, and 7 patients took 325 mg (regular strength) daily; aspirin dose was not specified for 36 patients but is assumed to be 81 or 325 mg daily based on the common medical dosages and no mention of highdose aspirin use in the medical records. Comorbidities that warranted long-term aspirin use among the patients followed by serial MRI scans are listed in Table 2 . The total number of comorbidities exceeded the total number of aspirin users because some patients had multiple comorbidities. Fourteen patients did not have any documented associated comorbidity, except age, which qualified them for aspirin prophylaxis against myocardial infarct or stroke. Among the patients followed with serial MRI scans, sVS demonstrated growth in 187 (54%), 33 (18%) of whom were aspirin users, and no growth in 160 (46%), 48 (30%) of whom were aspirin users ( Table 1 ). The difference in sVS growth versus no growth between aspirin users and nonusers was statistically significant (p = 0.0076; OR: 0.50; 95% CI, 0.29Y0.85; Table 3 ) and not confounded by age (p = 0.9) or sex (p = 0.6). However, we also performed age-adjusted analysis because the mean age of aspirin users (68.60 yr) was significantly different (p = 0.001) from the mean age of nonusers (63.08 years, as illustrated in Fig. 1A) , and sVS growth rate can be significantly inversely correlated with age (17) , which influences therapeutic decisions. Age-adjusted analysis was performed by selecting the nonusers (average age, 66.34 yr) that closely matched in age aspirin users so that there was no statistically significant difference between the 2 groups (p = 0.10, Fig. 1A, Table 3 ). Our age-adjusted analysis again revealed a significant difference in sVS growth versus no growth between aspirin users and age-matched nonusers (p = 0.0061; OR = 0.47; 95% CI, 0.27Y0.83).
The average tumor size at the time of the first MRI, expressed as mean T standard error of the mean, was 10.3 T 0.74 mm for aspirin users, and 10.5 T 0.45 mm for ageadjusted nonusers ( Fig. 2A) , which was not significantly different between the 2 groups (p = 0.89). When analyzing sVS growth rate numerically, as opposed to categorically, there was a trend toward less growth among aspirin users (0.865 T 0.18 mm/yr) versus nonusers (1.23 T 0.12 mm/yr) (Fig. 2B) . However, the trend did not meet our criterion for significance (p = 0.11).
DISCUSSION
We demonstrate, for the first time, inverse association between aspirin intake and sVS growth rate, categorized as growth versus no growth. A trend toward a similar inverse association was observed when tumor growth rate was quantified (in mm/yr), although this trend was not significant. We believe that categorical classification is more appropriate for our sample size because sVS growth rates varied substantially among tumors. Previous work hints to a biological basis for sVS responsiveness to aspirin as genes that mediate inflammation and that are known targets of aspirin signaling, such as COX-2 and NF-JB, are upregulated in sVS (9) . Unlike most other solid tumors, sVS have the characteristic of being stable without tumor progression for potentially decades, which is poorly understood (6) . It may be that the tumors are highly susceptible to ''off-target'' effects of herbs and medicines, such as aspirin, that people take for unrelated reasons.
Although sex does not correlate with sVS growth rate and is not a confounding variable in this and other (17, 18) studies, aspirin is known to have a sex-based effect in some contexts (19, 20) . For example, aspirin's role in triggering anti-inflammatory 15-Epi-Lipoxin A4 formation is more potent in women (20) . Our study's sex distributions, reflecting more men among aspirin users and more women among aspirin nonusers, fit the general finding that women are less likely to take aspirin regularly than men, and are also less likely to disclose contraindications that lead to aspirin intake (21) .
A potential use of aspirin to control sVS growth has many attractive features, including its ease of use, a generally favorable side-effect profile, and association with reduced risk of other diseases such as different types of cancer or cardiovascular disease (11) . The potential benefits will need to be balanced against potential harmful effects of long-term aspirin use, such as gastrointestinal bleeding and peptic ulcer disease (22, 23) . In the future, it The sum total of comorbidities supersedes the total number of aspirin users because some patients had multiple comorbidities.
a Men over the age of 45 and women older than 55 are recommended to take aspirin as prophylaxis against myocardial infarct and stroke, respectively (16) . will be important to understand whether aspirin's efficacy holds only through long-term usage or if it can be administered intermittently to maximize the therapeutic effect while minimizing toxicity.
It is important to note that our study relied on retrospective reporting of medication use, which is subject to error, particularly underreporting. For recall bias to explain our findings, patients with growing tumors would have to underreport usage more than patients with stable tumors, a possibility that is not likely as the patients with growing tumors are more likely to seek health care and be thorough in their information exchange with the physicians. As it is possible that we have not included all the confounders that affect the data, and because this is the first study to assess the potential therapeutic effect of aspirin in sVS, it will be important to replicate our findings in larger cohorts, and ideally in prospective clinical trials, before drawing definite conclusions.
CONCLUSION
Our findings, in line with the pathologic immunologic response present in sVS, emphasize the potential therapeutic value of aspirin in patients with sVS. Overall, the results of this study motivate future prospective clinical trials to test the value of using aspirin to modulate sVS growth.
